Precision Neuroscience is a technology company.
Precision Neuroscience has raised $161.0M across 2 funding rounds.
Precision Neuroscience has raised $161.0M in total across 2 funding rounds.
Precision Neuroscience has raised $161.0M in total across 2 funding rounds.
Precision Neuroscience's investors include Allos Ventures, Alumni Ventures, B Capital Group, Silverton Partners.
Precision Neuroscience is a neurotechnology company developing minimally invasive brain-computer interfaces (BCIs) to treat neurological disorders affecting over a billion people worldwide.[1][2][3][4] Its core product, the Layer 7 Cortical Interface, is a thin-film microelectrode array that records high-resolution brain signals from the brain's surface without penetrating or damaging tissue, enabling patients with conditions like paralysis and speech deficits to control digital devices through thought.[1][2][4] The company serves patients with severe neurological illnesses, healthcare providers, and clinical partners such as Rockefeller Neuroscience Institute, Mount Sinai Health System, and Penn Medicine, addressing the problem of limited communication and mobility by translating brain signals into actions.[1][4] Founded in 2021, Precision achieved FDA clearance for its device in 2025—remarkable in just four years—and is expanding clinical trials while manufacturing in-house, with commercial rollout anticipated soon.[1][2]
Precision Neuroscience was co-founded in 2021 by Ben Rapoport, a neurosurgeon-engineer with an MD from Harvard and PhD from MIT, and Michael Mager, a business builder.[1][2] Rapoport, previously on Neuralink's eight-member founding team and a practicing neurosurgeon at Mount Sinai specializing in minimally invasive procedures, had spent nearly two decades developing BCI technology; his vision was a high-bandwidth brain connection without penetrating electrodes that cause tissue damage.[1][2] Mager partnered with him to bring this to healthcare, starting with a four-person team—three from Neuralink.[2] Early traction came swiftly: they developed the Layer 7 interface, began patient testing, secured FDA clearance in 2025, and raised $41 million in Series B funding, hitting milestones that turned a novel idea into clinical reality.[1][2][4]
Precision stands out in the BCI field through these key advantages:
Precision Neuroscience rides the exploding brain-computer interface trend, merging AI, neuroscience, and neurotech to restore function for neurological patients amid rising demand from aging populations and conditions like paralysis.[1][3][4] Timing is ideal post-2025 FDA clearance, outpacing rivals in non-invasive high-res tech, fueled by market forces like AI advancements in signal processing and investor interest (e.g., Draper Associates, $41M Series B).[3][4] It influences the ecosystem by pioneering safer BCIs—first without open surgery for high-bandwidth use—partnering with top institutes, publishing innovations, and enabling thought-controlled devices, potentially expanding to broader human-AI interfaces while prioritizing medical applications.[1][2][4]
Precision is poised for commercial launch of Layer 7 soon after 2025 FDA clearance, scaling clinical trials and manufacturing to reach millions with paralysis, speech loss, or other deficits.[1][2] Trends like AI-driven neural decoding and regulatory momentum will accelerate adoption, with expansions into workforce reintegration and daily independence.[1][4] Its influence may evolve from medical pioneer to ecosystem leader, bridging human intelligence and AI safely—first-mover edge in non-damaging BCIs positions it to redefine neurotech, fulfilling the founding dream of damage-free brain connections.[2][3]
Precision Neuroscience has raised $161.0M across 2 funding rounds. Most recently, it raised $120.0M Series C in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $120.0M Series C | Allos Ventures, Alumni Ventures, B Capital Group, Silverton Partners | |
| Jan 1, 2023 | $41.0M Series B | Alumni Ventures, Silverton Partners |